natgillin/translations-raw huggingface dataset:
(18.0%), tremor (17.5%), neutropenia (17.5%), abdominal pain (16.9%), insomnia (15.3%), fatigue (15.3%) and chills (15.3%).
tremor (17,5%), neutropenija (17,5%), bol u abdomenu (16,9%), nesanica (15,3%), umor (15,3%) i zimica (15,3%).
(19.1-30.8)
(mjeseci) (95%CI)
(1st time)
(1. put)
(1st time)
(2./3. put)
(2 mg single dose)/
(2 mg u jednokratnoj
(2 mg single dose/600 mg once daily)
(2 mg u jednokratnoj dozi/600 mg
(2 mg single dose/600 mg once daily)
lorazepam/efavirenz (2 mg u jednokratnoj dozi/600 mg jedanput na dan)
(2 mg single dose/600 mg once daily)
valproična kiselina/efavirenz (250 mg dvaput na dan/600 mg jedanput na dan)
(2 patients) and major haematologic response (MaHR) (1 patient) with 1 patient still on treatment.
MaHR, major hematologic response) (1 bolesnik), s jednim bolesnikom još na liječenju.
(2 subjects)
(2 pacijenta)
(2 weeks)
(2 tjedna)
(2 x 1000 mg)
MabThera + metotreksat (2 x 1000 mg)
(2) Do not touch red button.
(2) Nemojte dirati
(2) Imatinib 36 MO:
(2) Imatinib 36 mj.:
(2) local adverse events associated with intravenous administration
(2)lokalne nuspojave povezane s intravenoznom primjenom
(2)A 10.5 mg/kg loading dose is recommended on the first day of treatment with levetiracetam. (3)A 15 mg/kg loading dose is recommended on the first day of treatment with levetiracetam. (4)Following dialysis, a 3.5 to 7 mg/kg supplemental dose is recommended.
(2)Prvog dana liječenja levetiracetamom preporučuje se udarna doza od 10,5 mg/kg. (3)Prvog dana liječenja levetiracetamom preporučuje se udarna doza od 15 mg/kg. (4)Nakon dijalize preporučuje se dodatna doza od 3,5 do 7 mg/kg.
(2,400 mg single
dozi)/elbasvir (50 mg u
(2,668 mg single
(2668 mg u jednokratnoj
(2.0, 14.8)
8,4% p=0,010 (2,0; 14,8)
(2.05-2.29)
pojedinačna
(2.06-5.16)
Kliničke napomene
(2.1+, 17.8+)
nije dosegnut (2,1+; 17,8+)
(2.29-4.27)
Metadon
(2.40-4.17)
vrijeme)
(20 mg single
(20 mg u jednokratnoj
(20-120 mg once
(20–120 mg jedanput na
(20-150 mg once
(20–150 mg jedanput na
(200 mg once
(200 mg jedanput na dan)
(200 mg once
(50 mg jedanput na dan)
(200 mg once
dan)/grazoprevir (200 mg
(200 mg once
dan)/tenofovir
(200 mg once
jedanput na dan)
(200 mg once daily
jedanput na dan)
(200 mg q12h/600 mg once daily)
(200 mg svakih 12h/600 mg
(200 mg single
(200 mg u jednokratnoj
(200 mg twice daily/400 mg once
(200 mg dvaput na dan /400 mg
(200 mg twice daily/400 mg once
(200 mg dvaput na dan/400 mg
(210/220)
ili virusno
(23.4%; 44.1%)c
(23,4%; 44,1%)c
(24.3%), hypokalaemia (23.8%), constipation (20.6%), anaemia (20.1%), cough (18.5%), diarrhoea
hipokalijemija (23,8%), konstipacija (20,6%), anemija (20,1%), kašalj (18,5%), proljev (18,0%),
(25 mg once daily)/
(25 mg jedanput na
(250/100 mg single dose/600 mg once daily)
karbamazepin/efavirenz (400 mg jedanput na dan/600 mg jedanput na dan)
(28 weeks)
(28 tjedana)
(2nd/3rd time)
(2./3. put)
(3 years post vaccination)
(3 godine na kon cijepljenja)
(3 years post vaccination)
(3 godine nakon cijepljenj a)
(3) A causal relationship between the medicinal product and the adverse event is at least a reasonable possibility.
(3) Uzročna povezanost lijeka s nuspojavom predstavlja barem razumnu mogućnost.
(30 mg/m2) every 3 weeks or PLD (50 mg/m2) every 4 weeks.
(30 mg/m2) svaka 3 tjedna ili PLD (50 mg/m2) svaka 4 tjedna.
(30 mL single dose/400 mg single
(30 ml u jednokratnoj dozi/400 mg
(300 kg bodyweight)
(300 kg tjelesne težine)
(300 mg once
(300 mg jedanput na
(300 mg once daily)
(300 mg jedanput na dan)
(300 mg once daily)/ elbasvir (50 mg once daily)
(300 mg jedanput na dan)/elbasvir (50 mg jedanput na dan)
(300 mg once daily)/ grazoprevir (200 mg once daily)
(300 mg jedanput na
(300 mg once daily/600 mg once
(300 mg jedanput na dan/600 mg
(300 mg twice daily*/100 mg
(300 mg dvaput na dan*/100 mg
(300 mg twice daily*/100 mg twice
(300 mg dvaput na dan*/100 mg
(300 mg)
10 kapsula (300 mg)
(300 mg)
4 kapsule (300 mg)
(34%, 78%)
p-vrijednost
(35-42 years of age) (body weight greater than or equal to 50 kg)
(u dobi od 35 do 42 godine) (tjelesna težina veća ili jednaka 50 kg)
(37.8 months)
(37,8 mjeseci)
(3x/wk, 4 or 8 wks)
8 tjedana)
(4 doses)
premnik (4 doze)
(4 mg single oral dose + Victrelis
(pojedinačna peroralna doza od
(4 weeks)
(4 tjedna)
(4) Following dialysis, a 3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) supplemental dose is recommended.
(4) Nakon dijalize preporučuje se dodatna doza od 3,5 do 7 mg/kg (0,035 do 0,07 ml/kg) .
(4) Following dialysis, a 3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) supplemental dose is recommended.
(4) Nakon dijalize preporučuje se dodatna doza od 3.5 do 7 mg/kg (0,035 do 0,07 ml/kg).
(4) Progression of pre-existing chronic myelomonocytic leukaemia with NRAS mutation.
(4) Progresija postojeće kronične mijelomonocitne leukemije s mutacijom gena NRAS.
(4.3, 16.8)
10,6% p<0,001 (4,3; 16,8)
(4.6-7.6)
(95%CI)
(40 mg once daily)/
(40 mg jedanput na dan)/
(40 mg single
(40 mg u jednokratnoj
(40 mg single dose/400 mg single
(40 mg u jednokratnoj dozi/400 mg
(40 mg/day)
(40 mg/dan)
(400 mg once daily/100 mg once
(400 mg jedanput na dan/100 mg
(400 mg once daily/200 mg once
(400 mg jedanput na dan/200 mg
(400 mg PO once
(400 mg peroralno
(400 mg single
(400 mg u jednokratnoj
(400 mg twice
(400 mg dvaput na
(400 mg twice daily/300 mg once
(400 mg dvaput na dan/300 mg
(400/100 mg twice daily/600 mg once daily)
(400/100 mg dvaput na dan/600 mg jedanput na dan)
(400/100 mg twice daily/600 mg once daily)
(500/125 mg dvaput na dan/ 600 mg jedanput na dan)
(40000 IU/ml)
1 ml (10000 IU/ml)
(40000 IU/ml)
1 ml (40000 IU/ml)
(402/709)
ili virusno
(44.0; 134)
W-135
(48.0% vs 40.8%) p=0.0148
(48,0% vs 40,8%) p=0,0148
(4th time)
(4. put)
(5 ml solvent)
(5 ml otapala)
(5 ml solvent) powder and solvent for solution for injection/infusion
(5 ml otapala) prašak i otapalo za otopinu za injekciju/infuziju
(5 ml solvent) powder and solvent for solution for injection/infusion
(5ml otapala) prašak i otapalo za otopinu za injekciju/infuziju
(5 years post vaccination)
(5 godina nakon cijepljenja)
(5) Following dialysis, a 5 to 10 mg/kg (0.05 to 0.10 ml/kg) supplemental dose is recommended.
(5) Nakon dijalize preporučuje se dodatna doza od 5 do 10 mg/kg (0,05 do 0,10 ml/kg) .
(5) Progression of pre-existing pancreatic adenocarcinoma with KRAS mutation.
(5) Progresija postojećeg adenokarcinoma gušterače s mutacijom gena KRAS.
(5)Following dialysis, a 5 to 10 mg/kg supplemental dose is recommended.
(5)Nakon dijalize preporučuje se dodatna doza od 5 do 10 mg/kg.
(5.8, NE) (4.7, 7.9)
(5,8; NE) (4,7; 7,9)
(50 mg once daily)
(50 mg jedanput na dan)
(50 mg once daily)
dan)/grazoprevir (200mg jedanput na dan)
(50 mg once daily)
dozi)/elbasvir (50 mg jedanput na dan)
(50 mg once daily)
jedanput na dan)
(50 mg once daily)/
jedanput na
(50 mg once daily)/
jedanput na dan)
(50 mg once daily)/
jedanput na dan)/grazoprevir (200 mg
(50 mg once daily)/
jedanput na dan)/grazoprevir (200 mg jedanput na dan)
(50 mg once daily/600 mg once
(50 mg jedanput na dan/600 mg
(50 mg single
(100 mg u jednokratnoj
(50 mg single
(50 mg u jednokratnoj
(50 mg single
jednokratnoj dozi)/grazoprevir
(50 mg single dose)
(50 mg u jednokratnoj
(50 mg single dose)
dozi)/elbasvir (50 mg u
(50 mg single dose)
jednokratnoj dozi)
(50 mg single dose)
u jednokratnoj dozi)
(500 mg q12h/400 mg once daily)
(500 mg svakih 12h/400 mg
(500 mg twice daily/600 mg once
(800 mg triput na dan/600 mg
(500 mg twice daily/600 mg once
ritonavir/efavirenz (500 mg dvaput na dan/600 mg jedanput na dan)
(500/125 mg twice daily/600 mg
raltegravir/efavirenz (400 mg u jednokratnoj dozi/ -)
(50doses)
100ml (50
(51.5% vs 48.5%) p=0.3037
(51,5% vs 48,5%) p=0,3037
(52 weeks)
(52 tjedna)
(6 mg/ml)
Volumen po dozi (6 mg/ml)
(6 Months of Complete Drug Withdrawal)
(6 mjeseci nakon potpunog prekida terapije)
(6 to 12 hours for patients under the
(6 do 12 sati u bolesnika mlađih
(6 to 12 hours for patients under the age
u bolesnika mlađih od 6 godina
(6 to 24 hours for patients under the
(6 do 24 sata u bolesnika mlađih
(6.2, 18.1)
12,1% p<0,001 (6,2; 18,1)
(60.6, 69.7) (p<0.0001)
(60,6, 69,7) (p<0,0001)
(600 mg IV single
(600 mg u jednokratnoj
(600 mg once
(600 mg jedanput na
(600 mg once daily/600 mg once
(600 mg jedanput na dan /600 mg
(600 mg once daily/600 mg once
(600 mg jedanput na dan/600 mg
(600 mg PO single
(600 mg u jednokratnoj
(600 mg twice
(600 mg dvaput na
(600 mg/ 200 mg/ 300 mg/ once daily)/ ledipasvir (90 mg once daily)c/ sofosbuvir (400 mg once daily)c, d
tenofovirdizoproksilfumarat (600 mg/ 200 mg/ 300 mg/ jedanput na dan)/ ledipasvir (90 mg jedanput na dan)c/ sofosbuvir (400 mg jedanput na dan)c, d
(600/100 mg twice daily) is used in
(600/100 mg dva puta na dan) uzima u
(600/100 mg twice daily) is used in combination with elvitegravir, the
(600/100 mg dva puta na dan) uzima u
(66, 154) (p<0.0001)
(66, 154) (p<0,0001)
(7.0-8.9 g/dl or any decrease
(7,0-8,9 g/dl ili bilo koje smanjenje
(70.2% vs 44.5%) p<0.0001
(70,2% vs 44,5%) p<0,0001
(72.9, 81.60) (p<0.0001)
(72,9, 81,6) (p<0,0001)
(73, 160) (p<0.0001)
(73, 160) (p<0,0001)
(75.6% vs 53.9%) p=0.0003
(75,6% vs 53,9%) p=0,0003
(750 mg q8h/600 mg once daily)
nelfinavir/efavirenz (750 mg svakih 8h/600 mg jedanput na dan)
(8 mg/2 mg single
(8 mg/2 mg u
(8 to 24 hours for patients under the
(8 do 24 sata u bolesnika mlađih
(8 to 24 hours for patients under the age
(8 do 24 sata u bolesnika mlađih
(8 to 24 hours for patients under the age
u bolesnika mlađih od 6 godina
(8-24 mg/2-6 mg
(8–24 mg/2–6 mg
(8.0 million IU) interferon beta-1b.
250 mikrograma (8,0 milijuna IU) interferona beta-1b.
(800 mg q8h/200 mg once daily)
(800 mg svakih 8h/200 mg
(800 mg q8h/200 mg once daily)
indinavir/efavirenz (800 mg svakih 8h/200 mg jedanput na dan)
(84%, 94%)b
73% (56/77)
(87%, 96%)b
Hispano-latino porijeklo
(88.4, 99.6)
tipa 16/18
(9.7 to 15.0)
(9,7 do 15,0)
(9.8; 859)
vaccine
(90 % CI 38-123 %)
(90% CI 38-123%)
(90 % CI 44-131 %)
(90% CI 44-131%)
(95 % CI)
(tjedni)
(95 % CI)
bez bolesti
(95 % CI)
preživljenja (tjedni)
(95 % CI)
Razlika† (95% CI)
(95 % CI)
vrijednosti
(95% CI of
(95% CI
(95% CI)
(-0,74; -0,45)
(95% CI)
19,7
(95% CI)
9,4 (6,6; 12,9)
(95% CI)
94,21
(95% CI) for ORRc
95% CI za ORRc
(95% confidence interval)
(interval pouzdanosti 95%)
(97.5% CI)
(97,5% CI)
(< 0.001)
> 54 tjedna (< 0,001)
(< 0.5 x 109/L) or thrombocytopenia (< 25  109/L) that results in more than 1
(< 0,5 x 109/L) ili thrombocitopenije (< 25  109/L) koji rezultira odgađanjem početka idućeg ciklusa za više od tjedan dana
(< 25,000/mm3)
(< 25 000/mm3)
(A ml Busilvex) x (10) = B ml of diluent
(A ml Busilvex) x (10) = B ml otapala
(A ml Busulfan Fresenius Kabi) x (10) = B ml of diluent
(A ml Busulfan Fresenius Kabi) x (10) = B ml otapala
(A ml Busulfan Fresenius Kabi) x (10) = B ml of diluent
(A ml lijeka Busulfan Fresenius Kabi) x (10) = B ml otapala
(a) Cimzia administered every 2 weeks preceded by a loading dose of 400 mg at Weeks 0, 2 and 4
(a) Cimzia primijenjena svaka 2 tjedna s prethodnom udarnom dozom od 400 mg u 0., 2. i 4. tjednu
(a) Cimzia all dosing regimen = data from Cimzia 200 mg administered every 2 weeks preceded by a loading dose of 400 mg at Weeks 0, 2 and 4 plus Cimzia 400 mg administered every 4 weeks preceded by a loading dose of 400 mg at Weeks 0, 2 and 4 (b) Results are from the randomized set (c) Wald p-values are quoted for the comparison of treatments using logistic regression with factors for treatment and region.
(a) Cimzia svi režimi doziranja = podaci kod 200 mg Cimzije primijenjene svaka 2 tjedna s prethodnom udarnom dozom od 400 mg u 0., 2. i 4. tjednu plus 400 mg Cimzije primijenjene svaka 4 tjedna s prethodnom udarnom dozom od 400 mg u 0., 2. i 4. tjednu (b) Rezultati su iz randomiziranog seta (c) p-vrijednosti po Waldu navedene su za usporedbu liječenja koristeći logističku regresiju uz faktore za liječenje i regiju.
(a) Patients were not censored at the time of cross-over
(a) Bolesnici nisu cenzurirani prilikom prelaska
(a) The intensity of clinical adverse events graded by the Common Terminology Criteria for Adverse Events v4.0 (CTC-AE).
(a) Intenzitet kliničkih nuspojava stupnjevan prema Zajedničkim terminološkim kriterijima za nuspojave (Common Terminology Criteria for Adverse Events, verzija 4.0, CTC-AE).
(A-Resistant Patients)
(Bolesnici bez odgovora na A)
(A-Responsive Patients)
(Bolesnici s odgovorom na A)
(acute) renal failure (severe kidney disorder)
(akutno) zatajenje bubrega (teški poremećaj bubrega)
(administered 12 hours
(primijenjen u razmaku
(administered in the evening)
(primijenjen
(affects 1 to 10 users in 1,000)
(pojavljuju se kod 1 do 10 bolesnika na 1000)
(affects 1 to 10 users in 100)
(pojavljuju se kod 1 do 10 bolesnika na 100)
(affects more than 1 user in 10)
(pojavljuju se kod više od 1 na 10 bolesnika)
(ALT, AST),
(ALT, AST), osobito na
(Amprenavir without
(Amprenavir bez ritonavira)
(as given in a
(primijenjen
(as tylvalosin tartrate)
(u obliku tilvalozin tartarata)
(at dose 340 mg/m2)
(doza od 340 mg/m2)
(at dose 400 mg)
(doza od 400 mg)
(at dose 800 mg)
(doza od 800 mg)
(at least 1 in 10 people are affected)
(javljaju se u najmanje 1 od 10 ljudi)
(atazanavir 300 mg / ritonavir
(atazanavir 300 mg/ritonavir
(atazanavir 300 mg and
(atazanavir 300 mg i ritonavir
(atazanavir 300 mg once daily
(atazanavir 300 mg jedanput na
(atazanavir 300 mg once daily with
(atazanavir 300 mg jedanput na dan i
(atazanavir 300 mg once daily with
dan, ujutro (atazanavir 300 mg
(atazanavir 400 mg once daily)
(atazanavir 400 mg jedanput na
(atazanavir 400 mg once daily,
(atazanavir 400 mg jedanput na dan,
(atazanavir 400 mg single dose)
(atazanavir 400 mg, jednokratna
(atorvastatin 40 mg single dose +
(atorvastatin pojedinačna doza od 40 mg + Victrelis 800 mg triput na
(attached as concertina label directly to the immediate package)
(pričvršćene izravno na unutarnje pakovanje)
(AUC) of darunavir by 40%,
darunaviru za 40%, primjerene
(b) Cimzia administered every 4 weeks preceded by a loading dose of 400 mg at Weeks 0, 2 and 4 (c) In subjects with at least 3% psoriasis BSA at Baseline
(b) Cimzia primijenjena svaka 4 tjedna s prethodnom udarnom dozom od 400 mg u 0., 2. i 4. tjednu (c) U ispitanika s barem 3% površine tijela zahvaćeno psorijazom na početku liječenja
(below the level of detection by the validated RT-PCR method at 3.14 log10 RNA copies/ml, indicating no infectious virus transmission)
(vrijednosti ispod razine otkrivanja validiranom RT-PCR metodom na 3,14 log10 RNA copies/ml, ukazuje na odsutnost virusa zaraze)
(below the level of detection by the validated RT-PCR method at 3.68 log10 RNA copies/ml, indicating no infectious virus transmission).
(*vrijednosti ispod razine otkrivanja validiranom RT-PCR metodom na 3,68 log10 RNA copies/ml, ukazuje na odsutnost virusa zaraze).
(Best Response Rate)
(Stopa najboljeg odgovora)
(bisphosphonat
femura
(bisphosphonate
leđima
(bisphosphonate
muskuloskeletalna
(BLISTER/ 7, 14, 28 or 84 tablets)
(BLISTER / 7, 14, 28 ili 84 tablete)
(blood uric acid increased)
(povišena mokraćna kiselina u krvi)
(blood uric acid increased)
bol u prsištua
(BOTTLE LABEL)
(NALJEPNICA BOCE)
(Box of 3 pipettes)
(Kutija s 3 pipete)
(buffered tablets) and stavudine.
(puferirane tablete) i stavudinom.
(buprenorphine/naloxone 8/2 –
(buprenorfin/nalokson 8/2
(by 9 %) compared to historical data was reported.
za 9% u usporedbi s povijesnom
(by 9%) compared to historical data
za 9% u usporedbi s povijesnom
(Card of 1 pipette)
(Kartica s 1 pipetom)
(Carton 250 IU/600 IU)
(Kutija 250 IU/600IU)
(CARTON OF MULTIPACK (12x 1 SINGLE PACKS) (INCLUDING BLUE BOX)
(KUTIJA S VIŠE PAKIRANJA (12x1 POJEDINAČNO PAKIRANJE) (UKLJUČUJUĆI PLAVI OKVIR)
(CARTON OF MULTIPACK (14x 1 SINGLE PACKS) (INCLUDING BLUE BOX)
(KUTIJA VIŠESTRUKOG PAKIRANJA (14x1 POJEDINAČNO PAKIRANJE) (UKLJUČUJUĆI PLAVI OKVIR)
(CARTON OF MULTIPACK (15x 1 SINGLE PACKS) (INCLUDING BLUE BOX)
(KUTIJA VIŠESTRUKOG PAKIRANJA (15x1 POJEDINAČNO PAKIRANJE) (UKLJUČUJUĆI PLAVI OKVIR)
(chelation of metal cations)
antacid s aluminijevim i magnezijevim hidroksidom
(CLcr < 30 mL/min, requiring dialysis)
(30  CLcr < 50 mL/min)
(CLcr < 30 mL/min, requiring dialysis)
Terminalni stadij bubrežne bolesti (CLcr < 30 mL/min, potrebna je dijaliza)
(co-formulated with
Bepridil Kinidin
(co-formulated with
Simeprevir Daklatazvir
(cobicistat 150 mg once daily)
(kobicistat 150 mg jedanput na dan)
(cognitively normal & clinical AD)
(normalna kognitivna funkcija i
(cognitively normal & MCI)
(normalna kognitivna funkcija i
(combination of OATP1B and CYP3A
(kombinacija mehanizama,
(combined atorvastatin groups)
(skupine koje su primale kombinaciju s atorvastatinom)
(combined rosuvastatin, simvastatin, & atorvastatin groups)
(skupine koje su primale kombinaciju s rosuvastatinom, simvastatinom i atorvastatinom)
(Common - may affect up to 1 in 10 people)
(Često - mogu se javiti u manje od 1 na 10 osoba)
(common - may affect up to 1 in 10 people)
(često – mogu se javiti u manje od 1 na 10 osoba)
(Common - may affect up to 1 in 10 people) lung infection (e.g. pneumonia, bronchitis)
(Često - mogu se javiti u manje od 1 na 10 osoba) infekcija pluća (npr. upala pluća, bronhitis)
(Common - may affect up to 1 in 10 people) severe wide-spread rash.
(Često - mogu se javiti u manje od 1 na 10 osoba) teški rasprostranjeni osip
(competitive inhibition of
(kompetitivna inhibicija oksidativnog
(competitive inhibition of oxidative
(kompetitivna inhibicija oksidativnog
(Complex binding to
(stvaranje kompleksa s
(concent
(koncent
(concentration)
(koncentracija)
(concentration)
takla
(confirmed by repeat testing, see section 4.4).
(potvrđeno ponovljenim testiranjem, vidjeti dio 4.4).
(Confirmed3) [95% CI]
(Potvrđeni3) [95% CI]
(CR/CRu) rate*
Stopa potpunog odgovora (CR/CRu)
(creatinine clearance estimated using Schwartz formula)
(klirens kreatinina procijenjen primjenom Schwartzove formule)
(cyclosporine 100 mg single dose +
(ciklosporin pojedinačna doza od
(cyclosporine 100 mg single dose +
(ciklosporin pojedinačna doza od 100 mg + Victrelis pojedinačna
(CYP induction by FPV/RTV)
(indukcija CYP lijekovima FPV/RTV)
(CYP1A2 substrate)
(supstrat CYP1A2)
(CYP2B6 induction)
(Indukcija CYP2B6)
(CYP2C9 substrate)
(supstrat CYP2C9)
(CYP2D6 and
(supstrat CYP2D6 i
(CYP2D6 and
CYP3A)
(CYP2D6 and/or CYP3A inhibition).
(CYP2D6 i/ili CYP3A inhibicija).
(CYP2D6 inhibition and/or P-gp)
(inhibicija CYP2D6 i/ili P-gp-a)
(CYP2D6 inhibition by
(inhibicija CYP2D6 lijekom RTV)
(CYP2D6 inhibition)
(CYP2D6 inhibicija)
(CYP2D6 substrate)
(supstrat CYP2D6)
(CYP3A and OATPB1
(inhibicija CYP3A i OATPB1)
(CYP3A and/or CYP2D6 inhibition)
(inhibicija CYP3A i/ili CYP2D6)
(CYP3A and/or P-gp inhibition).
(CYP3A i/ili P-gp inhibicija).
(CYP3A enzyme induction)
(indukcija enzima CYP3A4)
(CYP3A enzyme inhibition)
Cmax: ↑ 1,6 puta (inhibicija enzima CYP3A)
(CYP3A induction - effect on
(indukcija CYP3A – učinak na
(CYP3A inhibition -
(inhibicija CYP3A – učinak na
(CYP3A inhibition - effect on
(inhibicija CYP3A – učinak na
(CYP3A inhibition and/or P-gp
(inhibicija CYP3A i/ili
(CYP3A inhibition – effect on
(CYP3A inhibicija – utjecaj na
(CYP3A inhibition – effect on
(CYP3A inhibicija – utjecaj na kvetiapin)
(CYP3A inhibition – effect on
(inhibicija CYP3A - učinak na sirolimus)
(CYP3A inhibition)
interakcija nije ispitivana (inhibicija CYP3A)
(CYP3A4 enzyme inhibition)
(inhibicija enzima CYP3A4)
(CYP3A4 induction by
(indukcija CYP3A4
(CYP3A4 induction by
(indukcija CYP3A4 lijekovima
(CYP3A4 induction by St. John’s wort)
(indukcija CYP3A4 Gospinom travom)
(CYP3A4 inhibition by
(inhibicija CYP3A4 lijekovima
(CYP3A4 inhibition by
(inhibicija CYP3A4 lijekovima FPV/RTV)
(CYP3A4 inhibition by FPV/RTV
(inhibicija CYP3A4 lijekovima FPV/RTV)
(CYP3A4 inhibition by FPV/RTV)
(Blaga indukcija CYP3A4)
(CYP3A4 inhibition by FPV/RTV)
(inhibicija CYP3A4 lijekovima
(CYP3A4 substrate)
(supstrat CYP3A4)
(d) Full Analysis Set NA = not available
(d) Set potpune analize NA = nije dostupno
(darunavir 600 mg / ritonavir 100 mg
(darunavir 600 mg/ritonavir
(Day 1) then 100 mg QD
(1. dan) zatim 100 mg QD
(days 1-21 of repeated 28-day cycles)
(od 1. do 21. dana u ponavljajućim 28-dnevnim ciklusima)
(decrease in itraconazole
(snižena koncentracija itrakonazola:
(decrease in lymphocytes) a, b
(smanjen broj limfocita) a, b
(deep partial and full thickness)
(duboke rane djelomične i pune debljine kože)
(delavirdine, efavirenz, etravirine, nevirapine)
(delavirdin, efavirenz, etravirin, nevirapin)
(dose approx. equivalent to two 4 g cloves of garlic daily) (unboosted saquinavir
Kapsule češnjaka (doza približno ekvivalentna količini od dva češnja od 4 g na dan)
(double-blind)
(dvostruko slijepo)
(DRESS)
DRESS)
(DRESS)
intersticijski
(DRESS), hypersensitivity (including angioedema and anaphylaxis)
(uključujući angioedem i anafilaksu)
(drospirenone
(drospirenon
(drug) hypersensitivity
preosjetljivost (na lijek)
(e.g. amitriptyline,
(npr. amitriptilin,
(e.g. azithromycin) may be
Može se razmotriti
(efavirenz 600 mg daily + Victrelis
(efavirenz 600 mg na dan +
(effect on P-gp transport in the
(učinak na transport P-gp-a u crijevima)
(escitalopram 10 mg single dose +
(escitalopram pojedinačna doza od
(etravirine 200 mg every 12 hours +
(etravirin 200 mg svakih 12 sati +
(EU) called Vfend.
Riječ je o „generičkom lijeku”.
(Eylea 2 mg every 8 weeks following 3 initial monthly doses) (N = 607)
(Eylea 2 mg svakih 8 tjedana nakon 3 početne mjesečne doze) (N = 607)
(Facial) flushing
crvenilo (lica) praćeno osjećajem užarenosti
(fentanyl) n=1271
(fentanil) n = 1271
(for 10 days)
(tijekom 10 dana)
(for 10 days)
Profilaktička doza (tijekom 10 dana)
(for 5 days)
(tijekom 5 dana)
(for 5 days)
Terapijska doza (tijekom 5 dana)
(For LIPROLOG suspensions cloudy insulins only)
(Samo za LIPROLOG suspenzije, tj. mutne inzuline)
(For Poland only) Teva Operations Poland Sp. z o.o.
(Odnosi se samo na Pojlsku) Teva Operations Poland Sp. z o.o.
(For Poland only) Teva Operations Poland Sp. z o.o.
(Samo za Poljsku) Teva Operations Poland Sp. z o.o.
(frequency cannot be estimated from the available data) General side effects: increased heart rate
(učestalost se ne može procijeniti na temelju dostupnih podataka) Opće nuspojave: ubrzani otkucaji srca.
(further reduction to 15 mg if 30 mg are not well tolerated)
(daljnje smanjenje na 15 mg ako se 30 mg ne podnosi dobro)
(G3/4: 0.6%)
venski poremećaji (G3/4: 0,6%)
(glass)
(staklo)
(glass)
EU/1/10/618/001
(glass)
štrcaljka (staklo)
(glass) (Luer Lock)
(staklo)
(glass) ampoule of 1,000 doses of vaccine, 5-ampoule carrier.
(staklena) ampula od 1,000 doza cjepiva, nosač s 5 ampula.
(glass) ampoule of 1,000 doses of vaccine, 5-ampoule carrier.
(staklena) ampula od 1.000 doza cjepiva, nosač s 5 ampula.
(glass) ampoule of 2,000 doses of vaccine, 4-ampoule carrier.
(staklena) ampula od 2.000 doza cjepiva, nosač s 4 ampula.
(glass) ampoule of 2,000 doses of vaccine, 4-ampoule carrier.
(staklena) ampula od 2.000 doza cjepiva, nosač s 4 ampule.
(glass) in pre-filled pen (OptiSet) cartridge
uložak (staklo) u napunjenoj brizgalici (OptiSet)
(glass) in pre-filled pen (SoloStar) cartridge
uložak (staklo) u napunjenoj brizgalici (SoloStar)
(glass) single dose vial
bočica (staklena) Jednodozna
(glass) with needle-trap pre-filled syringe
Napunjena štrcaljka (staklo) sa štitnikom igle Napunjena štrcaljka (staklo) sa štitnikom igle Napunjena štrcaljka (staklo)
(glass) with needle-trap pre-filled syringe
napunjene štrcaljke
(glass) with needle-trap pre-filled syringe
napunjenih štrcaljki
(glass) with needle-trap pre-filled syringe
štrcaljka (staklo)
(glass) with needle-trap pre-filled syringe
štrcaljka (staklo) s klopkom za iglu napunjena
(glass) with needle-trap pre-filled syringe
štrcaljka (staklo) sa štitnikom igle Napunjena
(glass); solvent: vial (glass)
(staklo); otapalo: bočica (staklo)
(glass); solvent: vial (glass) powder: vial
(staklo); otapalo: bočica (staklo)
(grading 0.1 ml)
0,1 ml)
(HCV-RNA Results†)
(razina HCV-RNK†)
(hip, radius, humerus,
kost, nadlaktična kost,
(ICU) or similar setting which
Agonisti Beta2-adrenoreceptora (dugodjelujući)
(ICU) or similar setting, which
Sedativi/hipnotici se
(ICU) or similar setting, which
vardenafilom ili tadalafilom, tada su
(Imlygic, n = 163;
Stadij§ IVM1B/ IVM1C (Imlygic, n = 131;
(immediate
ti (trenutne
(incl.
(uključujući
(including
(uključujući
(including cysts and
novotvorine (uključujući
(including cysts and polyps)
novotvorine (uključujući ciste i polipe)
(including hematoma,
na mjestu primjene